STAT on Stateside Daily

STAT+: Lawmakers urge HHS to force Eli Lilly to provide 340B drug discounts to hospitals

STAT2d ago

STAT+: Elevance sues government over $115 million tied to Medicare Advantage star ratings

STAT3d ago

STAT+: Up and down the ladder: The latest comings and goings

STAT3d ago2 sources

STAT+: What does DeGette’s loss mean for pharma?

STAT3d ago

STAT+: Roche drug sets new standard for KRAS-driven lung cancer

STAT3d ago

STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and more

STAT3d ago

STAT+: U.S. judge blocks Colorado’s first-of-its-kind price cap on an Amgen drug

STAT3d ago

STAT+: More frequent, more intense, and longer heat waves pose health risks for Americans

STAT3d ago

STAT+: Halfway into the year, biotech is booming

STAT3d ago

The new presidential fitness test is a positive step, not the solution, experts say

STAT3d ago

Opinion: CDC leadership continues to try to manufacture a scientific debate on vaccines where none exists

STAT3d ago

STAT+: A ‘historic’ FDA clearance raises the question: Is the LLM an interface or the decision-maker?

STAT3d ago

STAT+: A former AI regulator, now in industry, says biopharma is reading FDA’s guidance wrong

STAT3d ago

Opinion: Teens are turning to chatbots for mental health help. We need rules to keep them safe

STAT3d ago

STAT+: A year after distressed buyout, what’s become of Bluebird Bio?

STAT3d ago

Statins and blood pressure drugs changing health risks of obesity, study suggests

STAT3d ago

STAT+: The moment Anthropic convinced me it’s serious about science

STAT4d ago

STAT+: Synthetic biology researchers think they’ve made a cell. Is it alive?

STAT4d ago

STAT+: Pharmalittle: We’re reading about Anthropic drug development goals, Trump drug plan snags, and more

STAT4d ago

STAT+: More signs that GLP-1s may help with peripheral artery disease

STAT4d ago

FDA says Zyn can market its pouches as safer than cigarettes

STAT4d ago

STAT+: FDA approves Orca Bio’s T cell therapy for blood cancer patients

STAT4d ago

STAT+: Talawar bets bispecific approach can shake up eczema market

STAT6d ago

STAT+: Pharmalittle: We’re reading about a broader $35 insulin cap, a former FDA cancer drug chief, and more

STAT6d ago

What’s next for 988 LGBTQ+ services?

STAT6d ago

STAT+: Sword Health contracted to provide AI-supported physical therapy for an entire country

STAT6d ago

STAT+: Moderna co-founder Kenneth Chien on the future of mRNA — and Moderna

STAT6d ago

STAT+: The ERs that can turn patients away — and are reaping millions

STAT6d ago

Opinion: STAT+: The U.S.-China biotech crackdown may hurt the scientists America needs the most

STAT6d ago

STAT

STAT+: Medicare takes another swing at 340B cuts to hospitals

STAT+: Medicare takes another swing at 340B cuts to hospitals

Latest from STAT

STAT+: Lawmakers urge HHS to force Eli Lilly to provide 340B drug discounts to hospitals

STAT+: Elevance sues government over $115 million tied to Medicare Advantage star ratings

STAT+: Up and down the ladder: The latest comings and goings

STAT+: What does DeGette’s loss mean for pharma?

STAT+: Roche drug sets new standard for KRAS-driven lung cancer

STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and more

STAT+: U.S. judge blocks Colorado’s first-of-its-kind price cap on an Amgen drug

STAT+: More frequent, more intense, and longer heat waves pose health risks for Americans

STAT+: Halfway into the year, biotech is booming

The new presidential fitness test is a positive step, not the solution, experts say

Opinion: CDC leadership continues to try to manufacture a scientific debate on vaccines where none exists

STAT+: A ‘historic’ FDA clearance raises the question: Is the LLM an interface or the decision-maker?

STAT+: A former AI regulator, now in industry, says biopharma is reading FDA’s guidance wrong

Opinion: Teens are turning to chatbots for mental health help. We need rules to keep them safe

STAT+: A year after distressed buyout, what’s become of Bluebird Bio?

Statins and blood pressure drugs changing health risks of obesity, study suggests

STAT+: The moment Anthropic convinced me it’s serious about science

STAT+: Synthetic biology researchers think they’ve made a cell. Is it alive?

STAT+: Pharmalittle: We’re reading about Anthropic drug development goals, Trump drug plan snags, and more

STAT+: More signs that GLP-1s may help with peripheral artery disease

FDA says Zyn can market its pouches as safer than cigarettes

STAT+: FDA approves Orca Bio’s T cell therapy for blood cancer patients

STAT+: Talawar bets bispecific approach can shake up eczema market

STAT+: Pharmalittle: We’re reading about a broader $35 insulin cap, a former FDA cancer drug chief, and more

What’s next for 988 LGBTQ+ services?

STAT+: Sword Health contracted to provide AI-supported physical therapy for an entire country

STAT+: Moderna co-founder Kenneth Chien on the future of mRNA — and Moderna

STAT+: The ERs that can turn patients away — and are reaping millions

Opinion: STAT+: The U.S.-China biotech crackdown may hurt the scientists America needs the most

Browse more

Reader

Trust & legal

Across the network

STAT

STAT+: Medicare takes another swing at 340B cuts to hospitals

STAT+: Medicare takes another swing at 340B cuts to hospitals

Latest from STAT

STAT+: Lawmakers urge HHS to force Eli Lilly to provide 340B drug discounts to hospitals

STAT+: Elevance sues government over $115 million tied to Medicare Advantage star ratings

STAT+: Up and down the ladder: The latest comings and goings

STAT+: What does DeGette’s loss mean for pharma?

STAT+: Roche drug sets new standard for KRAS-driven lung cancer

STAT+: Pharmalittle: We&#8217;re reading about a court win for Amgen, Novo seeking supplier discounts, and more

STAT+: U.S. judge blocks Colorado&#8217;s first-of-its-kind price cap on an Amgen drug

STAT+: More frequent, more intense, and longer heat waves pose health risks for Americans

STAT+: Halfway into the year, biotech is booming

The new presidential fitness test is a positive step, not the solution, experts say

Opinion: CDC leadership continues to try to manufacture a scientific debate on vaccines where none exists

STAT+: A ‘historic’ FDA clearance raises the question: Is the LLM an interface or the decision-maker?

STAT+: A former AI regulator, now in industry, says biopharma is reading FDA&#8217;s guidance wrong

Opinion: Teens are turning to chatbots for mental health help. We need rules to keep them safe

STAT+: A year after distressed buyout, what’s become of Bluebird Bio?

Statins and blood pressure drugs changing health risks of obesity, study suggests

STAT+: The moment Anthropic convinced me it’s serious about science

STAT+: Synthetic biology researchers think they’ve made a cell. Is it alive?

STAT+: Pharmalittle: We&#8217;re reading about Anthropic drug development goals, Trump drug plan snags, and more

STAT+: More signs that GLP-1s may help with peripheral artery disease

FDA says Zyn can market its pouches as safer than cigarettes

STAT+: FDA approves Orca Bio’s T cell therapy for blood cancer patients

STAT+: Talawar bets bispecific approach can shake up eczema market

STAT+: Pharmalittle: We&#8217;re reading about a broader $35 insulin cap, a former FDA cancer drug chief, and more

What’s next for 988 LGBTQ+ services?

STAT+: Sword Health contracted to provide AI-supported physical therapy for an entire country

STAT+: Moderna co-founder Kenneth Chien on the future of mRNA — and Moderna

STAT+: The ERs that can turn patients away — and are reaping millions

Opinion: STAT+: The U.S.-China biotech crackdown may hurt the scientists America needs the most

Browse more

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and more

STAT+: U.S. judge blocks Colorado’s first-of-its-kind price cap on an Amgen drug

STAT+: A former AI regulator, now in industry, says biopharma is reading FDA’s guidance wrong

STAT+: Pharmalittle: We’re reading about Anthropic drug development goals, Trump drug plan snags, and more

STAT+: Pharmalittle: We’re reading about a broader $35 insulin cap, a former FDA cancer drug chief, and more